News & Media

SK Life Science

Welcome to the news and information center for SK Life Science, Inc. (SKLSI), a CNS-focused pharmaceutical company

General business

Strategic alliance and partnership opportunities

Media inquiries and PR

Grant and investigator initiated proposals

Sponsorship requests

Medical information inquiries or report adverse events

SK Life Science at a glance

  • Headquarters location


  • R&D Begins


  • Parent Company

    SK Life Science is a subsidiary of SK Biopharmaceuticals, Co., Ltd., and both are part of the SK Group

  • Number of employees

    200+ EMPLOYEES

  • Disease Category Focus


  • Pipeline

    8 compounds under clinical development


Latest XCOPRI® (cenobamate tablets) CV Post-hoc Analysis Presented at the 75th American Academy of Neurology Annual Meeting

Full release

SK Life Science CEO, Donghoon Lee, Shares His Vision for the Company and Energizes Workforce Meeting in San Diego This Week

Full release

SK Biopharmaceuticals Unveils Vision for Digital Healthcare

Full release

SK Biopharmaceuticals’ Partner Angelini Pharma Launches Cenobamate in France

Full release

SK Biopharmaceuticals Wins Export Award for Cenobamate

Full release

Seoul National University Bundang Hospital Presents Study of SK Biopharmaceuticals’ Seizure Detection Wearable Device at AES 2022

Full release

SK life science Presents Latest Data on XCOPRI® (cenobamate tablets) CV in Adults with Partial-Onset (Focal) Seizures at the AES 2022 Annual Meeting

Full release

SK Biopharmaceuticals Names Donghoon Lee, Head of Bio Investment Center of SK Inc., as New CEO

Full release

SK life science To Present Latest XCOPRI® (cenobamate tablets) CV Data at the American Epilepsy Society 2022 Annual Meeting

Full release

SK Biopharmaceuticals Named CES 2023 Innovation Awards Honoree

Full release